ESMO 2017: FOLFOX4/XELOX in stage II–III colon cancer: efficacy and safety results

Among the 6 randomised comparisons between 6 months and 3 months of adjuvant FOLFOX/XELOX for early stages colon cancer of the IDEA collaboration (International Duration Evaluation of Adjuvant), TOSCA was the first to start and the first to close the...

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2eOmKAI
via IFTTT